| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Aeglea BioTherapeutics Inc (NASDAQ: AGLE)
AGLE Technical Analysis
5
| As on 9th Jun 2023 AGLE STOCK Price closed @ 0.13 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.70 & Strong Sell for SHORT-TERM with Stoploss of 3.81 we also expect STOCK to react on Following IMPORTANT LEVELS. |
AGLESTOCK Price
| Open | 0.13 | Change | Price | % |
| High | 0.15 | 1 Day | 0.00 | 0.00 |
| Low | 0.13 | 1 Week | 0.00 | 0.00 |
| Close | 0.13 | 1 Month | -0.03 | -18.75 |
| Volume | 1271400 | 1 Year | -3.96 | -96.82 |
| 52 Week High 4.77 | 52 Week Low 0.13 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| AGLE Daily Charts |
AGLE Intraday Charts |
Whats New @ Bazaartrend |
AGLE Free Analysis |
|
|
AGLE Important Levels Intraday
| RESISTANCE | 0.17 |
| RESISTANCE | 0.16 |
| RESISTANCE | 0.15 |
| RESISTANCE | 0.14 |
| SUPPORT | 0.12 |
| SUPPORT | 0.11 |
| SUPPORT | 0.10 |
| SUPPORT | 0.09 |
AGLE Forecast May 2024
| 4th UP Forecast | 3.27 |
| 3rd UP Forecast | 2.26 |
| 2nd UP Forecast | 1.64 |
| 1st UP Forecast | 1.02 |
| 1st DOWN Forecast | -0.76 |
| 2nd DOWN Forecast | -1.38 |
| 3rd DOWN Forecast | -2 |
| 4th DOWN Forecast | -3.01 |
AGLE Weekly Forecast
| 4th UP Forecast | 1.67 |
| 3rd UP Forecast | 1.18 |
| 2nd UP Forecast | 0.87 |
| 1st UP Forecast | 0.57 |
| 1st DOWN Forecast | -0.31 |
| 2nd DOWN Forecast | -0.61 |
| 3rd DOWN Forecast | -0.92 |
| 4th DOWN Forecast | -1.41 |
AGLE Forecast2024
| 4th UP Forecast | 9.23 |
| 3rd UP Forecast | 6.31 |
| 2nd UP Forecast | 4.51 |
| 1st UP Forecast | 2.7 |
| 1st DOWN Forecast | -2.44 |
| 2nd DOWN Forecast | -4.25 |
| 3rd DOWN Forecast | -6.05 |
| 4th DOWN Forecast | -8.97 |
Aeglea BioTherapeutics Inc ( NASDAQ USA Symbol : AGLE )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AGLE Business Profile
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Address: 805 Las Cimas Parkway, Austin, TX, United States, 78746
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service